For the quarter ending 2026-03-31, URGN had -$800K decrease in cash & cash equivalents over the period. -$45,370K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -23,574 | -26,364 | -33,347 | -93,783 |
| Restricted deposit | - | 0 | 0 | -1 |
| Depreciation and amortization | 75 | 75 | 80 | 152 |
| Accrued financing on prepaid forward obligation | 1,059 | 1,270 | 1,472 | 123 |
| Amortization (accretion) on marketable securities | -26 | 75 | 160 | 1,640 |
| Share-based compensation | 4,627 | 3,130 | 3,027 | 5,802 |
| Amortization of discount on long-term debt | 1,974 | 99 | -397 | 774 |
| Amortization of right of use assets | 577 | 604 | 559 | 941 |
| Acquisitions of ipr&d | 0 | 0 | 0 | 3,128 |
| Inventory | 4,457 | 8,123 | 1,213 | -2,099 |
| Accounts receivable, net | 22,330 | 13,379 | 54 | -653 |
| Prepaid expenses and other current assets | 4,858 | 2,550 | 67 | 3,210 |
| Other non-current assets | 2,332 | -1,598 | 5,958 | 212 |
| Accounts payable and accrued expenses | 7,629 | 1,544 | -4,789 | 3,531 |
| Employee related accrued expenses | -3,679 | 2,402 | -532 | 1,076 |
| Other current liabilities | 0 | -1 | -263 | 62 |
| Uncertain tax positions | - | 112 | - | - |
| Lease liabilities | -53 | 1,333 | -628 | -1,344 |
| Net cash used in operating activities | -45,316 | -38,325 | -42,270 | -81,849 |
| Purchases of marketable securities | 24,780 | 539 | 8,721 | 68,140 |
| Maturities of marketable securities | 4,146 | 28,273 | 40,206 | 70,768 |
| Purchases of property and equipment | 54 | 17 | 87 | 185 |
| Net cash used in investing activities | -20,688 | 27,717 | 31,398 | 2,443 |
| Principal payments on finance leases | 321 | 1,855 | - | - |
| Proceeds from exercise of options into ordinary shares | 179 | 1,343 | 302 | 327 |
| Proceeds from issuance of long-term debt, net | 65,346 | 0 | 0 | - |
| Proceeds from pre-funded warrant issuance, net of issuance costs | - | -3 | 0 | 3 |
| Proceeds from ordinary shares issuances, net of issuance costs | 0 | 31,831 | 7,970 | 0 |
| Net cash provided by financing activities | 65,204 | 31,316 | 8,272 | 330 |
| Decrease in cash and cash equivalents | -800 | 20,708 | -2,600 | -79,076 |
| Cash, cash equivalents and restricted cash at beginning of period | 112,095 | 91,386 | 173,062 | - |
| Cash, cash equivalents and restricted cash at end of period | 111,295 | 112,095 | 91,386 | - |
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)